TerminatedPhase 2

A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip

Stopped: Study was stopped due to business decision and lack of enrollment. There were no safety concerns.

United States1 participantsStarted 2025-07-25

Plain-language summary

The goal of this clinical trial is to evaluate an injection procedure for the investigational drug in people with Osteoarthritis of the Hip. The Sponsor is conducting this research to evaluate successful injections in the hip by using two different needle sizes.

Who can participate

Age range

50 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Participants must provide written informed consent prior to initiating any study specific procedures.
. Participants must be willing and able to comply with the study procedures and visit schedule and to follow verbal and written instructions.
. Participants must be male or female and 50 to 80 years old, inclusive, on the day of consent.
. Participants must have a body mass index (BMI) ≤40 kg/m2 at Screening.
. Participants must exhibit symptoms associated with unilateral or bilateral hip OA for at least 6 months prior to Screening.
. Participants with unilateral or bilateral hip pain must have a 24-hour average pain score (based on a numerical rating scale \[NRS\]) between ≥5.0 and ≤9.0 for the index hip and \<5 in contralateral hip at Screening.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Assessment of Successful Hip injection Rate

Timeframe: Day 1

Trial details

NCT IDNCT06977568

SponsorPacira Pharmaceuticals, Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-10-16

View on ClinicalTrials.gov More Osteoarthritis of Hip trials

Who can participate

Age range

50 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Participants must provide written informed consent prior to initiating any study specific procedures.
. Participants must be willing and able to comply with the study procedures and visit schedule and to follow verbal and written instructions.
. Participants must be male or female and 50 to 80 years old, inclusive, on the day of consent.
. Participants must have a body mass index (BMI) ≤40 kg/m2 at Screening.
. Participants must exhibit symptoms associated with unilateral or bilateral hip OA for at least 6 months prior to Screening.
. Participants with unilateral or bilateral hip pain must have a 24-hour average pain score (based on a numerical rating scale \[NRS\]) between ≥5.0 and ≤9.0 for the index hip and \<5 in contralateral hip at Screening.

A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Exclusion criteria